Rate My Professor Jessica Cale

Since 2021, Dr. Cale has been involved in commercial-in-confidence industry-funded research contracts with Senisca Ltd. in the UK and Lyramid Ltd. in Australia, developing antisense oligonucleotide therapies for healthy aging and cancer; this work led to her being named an inventor on an international patent application. She serves as a senior postdoctoral scientist on a multi-year research program funded by Sarepta Therapeutics in the US. Her publications include 'Proof-of-Concept: Antisense Oligonucleotide Mediated Exon Skipping as a Therapeutic Strategy for Malan Overgrowth Syndrome' (Genes, 2021), 'Induced alternative splicing: an opportunity to study PCSK9 protein isoforms at physiologically relevant concentrations' (Scientific Reports, 2023), 'A Patient Case of Malan Syndrome Involving 19p13.2 Microduplication Including NOTCH1: Exploring Therapeutic Potential' (Genes, 2024), 'Is Exon Skipping a Viable Therapeutic Approach for Vascular Ehlers-Danlos Syndrome?' (Journal of Personalized Medicine, 2024), and contributions to 'Overgrowth-intellectual disability disorders: progress in biology, patient advocacy, and innovative therapies' (2025). In 2025, she received the Early-Mid Career Researcher Aspire Award from Business Events Perth. Cale supervises honours and PhD students, including projects in PC2 facilities, and participates in grant-funded research such as the Malan Syndrome Foundation grant.